HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.17 billion market cap medical device company with a FAIR financial health rating according to InvestingPro, has enrolled the first patient ...
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence ...
A Wellington doctor is leading the way in New Zealand with a surgery that can give young people a hope of having children years after fertility-destroying treatments. Dr Leigh Searle, the only doctor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback